Back to top

crispr: Archive

Zacks Equity Research

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.

ALLONegative Net Change FULCNegative Net Change IMTXPositive Net Change TRDAPositive Net Change

Ahan Chakraborty

Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?

Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

VRTXPositive Net Change MRNANegative Net Change CRSPNegative Net Change